Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

BACKGROUND: Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies-Gow, Andrew, Gurnell, Mark, Heaney, Liam G., Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Harrison, Timothy, Jackson, David J., Price, David, Lugogo, Njira, Kreindler, James, Burden, Annie, de Giorgio-Miller, Alex, Faison, Sarai, Padilla, Kelly, Martin, Ubaldo J., Garcia Gil, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791910/
https://www.ncbi.nlm.nih.gov/pubmed/35896216
http://dx.doi.org/10.1183/13993003.03226-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791910/
https://www.ncbi.nlm.nih.gov/pubmed/35896216
http://dx.doi.org/10.1183/13993003.03226-2021

Ejemplares similares